Vascular Injury - Pipeline Review, H1 2014

Vascular Injury - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Vascular Injury - Pipeline Review, H1 2014’, provides an overview of the Vascular Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vascular Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vascular Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vascular Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vascular Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vascular Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vascular Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vascular Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vascular Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vascular Injury Overview 6
Therapeutics Development 7
Pipeline Products for Vascular Injury - Overview 7
Pipeline Products for Vascular Injury - Comparative Analysis 8
Vascular Injury - Therapeutics under Development by Companies 9
Vascular Injury - Therapeutics under Investigation by Universities/Institutes 10
Vascular Injury - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Vascular Injury - Products under Development by Companies 13
Vascular Injury - Products under Investigation by Universities/Institutes 14
Vascular Injury - Companies Involved in Therapeutics Development 15
Advanced Cell Technology, Inc. 15
Shire Plc 16
Polyphor Ltd. 17
ChemoCentryx, Inc. 18
Vascular Injury - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
SHP-613 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Hemangioblast Program - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CCX-872 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
POL-5551 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Stem Cell Therapy for Vascular Injury - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Vascular Injury - Recent Pipeline Updates 35
Vascular Injury - Dormant Projects 37
Vascular Injury - Product Development Milestones 38
Featured News & Press Releases 38
Nov 08, 2013: Proteo, Inc. / Proteo Biotech AG: Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed 38
Nov 16, 2012: Bio3 Research Receives Hong Kong Patent For HMGB1 Antibodies To Treat Vascular Diseases 38
Jan 10, 2012: Amorcyte Announces Expansion Of Intellectual Property Coverage For AMR-001 38
Mar 30, 2009: Amorcyte Reports Phase I Results Of AMR-001 To Improve Recovery From Severe Heart Attack At ACC Annual Scientific Session 39
Apr 01, 2008: Amorcyte Completes Phase I Trial Of Stem Cell Therapy For Acute Myocardial Infarction 40
May 08, 2007: Amorcyte Cardiac Cell Therapy Trial Completes Second Of Four Phases 41
Jun 05, 2006: Amorcyte, Inc Opens Cell Therapy Trial For Cardiovascular Disease At Emory University 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products under Development for Vascular Injury, H1 2014 7
Number of Products under Development for Vascular Injury - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Vascular Injury - Pipeline by Advanced Cell Technology, Inc., H1 2014 15
Vascular Injury - Pipeline by Shire Plc, H1 2014 16
Vascular Injury - Pipeline by Polyphor Ltd., H1 2014 17
Vascular Injury - Pipeline by ChemoCentryx, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Vascular Injury Therapeutics - Recent Pipeline Updates, H1 2014 35
Vascular Injury - Dormant Projects, H1 2014 37

List of Figures
Number of Products under Development for Vascular Injury, H1 2014 7
Number of Products under Development for Vascular Injury - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27